B+
Bull case
25%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
CRMD
CorMedixANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
DefenCath commercial execution, strong Q2 profitability, a raised FY2026 EBITDA outlook, $256.7 million of cash and short-term investments, and potential REZZAYO label expansion provide multiple value drivers [#SEC-8K-2026-08-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.2.
What can break
DefenCath demand or reimbursement could weaken as the post-TDAPA environment evolves.
Momentum
52
Value
73
Sentiment
75
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.75 · Bull $12.00 · Bear $5.75Analysis 2026-08-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $15.40
Why
Momentum52 · Δ7d -26.7
Value73 · Δ7d -0.0
Sentiment75 · Δ7d +10.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +10.2.
Contradictions & invalidation
- • DefenCath demand or reimbursement could weaken as the post-TDAPA environment evolves.
- • Low coverage and unavailable analyst revisions, options, short-interest, and social data limit independent validation.
- • The thesis depends on sustained DefenCath utilization through the post-TDAPA reimbursement transition, successful REZZAYO regulatory progress, and execution on pipeline programs.
Catalyst clock
2026-11-23
REZZAYO prophylaxis sNDA submission
Lead driver: Sentiment · See AI snapshot
Momentum
52
9% active weight
Current posture
7d trendSoftening
Δ7d
-26.7
Δ21d
+31.5
Value
73
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.0
Sentiment
75
62% active weight
Current posture
7d trendImproving
Δ7d
+10.2
Δ21d
-20.3
Why this grade
Composite grade A. Momentum 52.3 / Value 72.9 / Sentiment 75.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$8.75
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$597.83M
Beta
1.40
Shares Out
77.94M
P/E (TTM)
5.9
P/S (TTM)
4.48
P/FCF (TTM)
12.91
Rev YoY
+156.5%
EPS YoY
+1.9%
Gross Margin
+82.8%
Op Margin
+47.0%
Net Debt
-$273K
Current Ratio
2.56
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data